Approximately 40% of papillary thyroid carcinomas (PTC) harbor the BRAF V600E mutation, which is significantly associated with the advanced clinico-pathological features of PTC at diagnosis, higher recurrence rate and disease-related mortality. BRAF alterations other than V600E are less common in PTC, and their clinical significance remains to be established.
Papillary Thyroid Carcinoma With Rare exon 15 BRAF Mutation Has Indolent Behavior: A Single-Institution Experience
Torregrossa, Liborio;VIOLA, DAVID;GIORDANO, MIRELLA;Piaggi, Paolo;ROMEI, CRISTINA;MATERAZZI, GABRIELE;MICCOLI, PAOLO;ELISEI, ROSSELLA;BASOLO, FULVIO
2016-01-01
Abstract
Approximately 40% of papillary thyroid carcinomas (PTC) harbor the BRAF V600E mutation, which is significantly associated with the advanced clinico-pathological features of PTC at diagnosis, higher recurrence rate and disease-related mortality. BRAF alterations other than V600E are less common in PTC, and their clinical significance remains to be established.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
